PROBIAL Baby GG

Lacticaseibacillus rhamnosus GG (LGG) is one of the most extensively researched and characterized probiotic strains globally, with over 30 years of clinical studies to its credit. Its broad range of benefits and applications, particularly in pediatric health, have been demonstrated through numerous in vitro and clinical studies [1].

• Antipathogenic Activity: LGG exhibits broad-spectrum antipathogenic activity against various gastric and enteric pathogens, including Shigella, various E. coli serotypes, Salmonella typhimurium, Helicobacter pylori, several rotaviruses, and Staphylococcus aureus. It has also been tested for antibiotic resistance and susceptibility across more than 20 different antibiotics.

• Gut Barrier Function: LGG effectively improves intestinal permeability by stimulating intestinal epithelial cell proliferation and enhancing the secretion of protective mucins.

• Colonization in Newborns: LGG is known to colonize the gut of newborns more effectively than in adults, leading to extensive research in pediatric subjects, particularly in pediatric diarrhea. Over 1000 publications and 300 clinical studies have been conducted in this area.

Clinical Studies and Applications:

• Infant Growth: Infants fed with LGG-enriched formula until the age of 6 months showed better growth compared to those fed with regular formula [2].

• Acute Diarrhea: Numerous clinical studies have demonstrated the efficacy of LGG in treating acute diarrhea in children, including its prophylactic use for acute gastroenteritis [3].

• Functional GI Disorders: Several studies have explored the role of LGG in abdominal pain-related functional GI disorders in childhood, such as IBS, functional dyspepsia, and functional abdominal pain [4].

• Antibiotic-Associated Diarrhea: LGG has shown significant efficacy in multiple meta-analyses examining antibiotic-associated diarrhea, including its use in H. pylori eradication therapy in children [5].

• Necrotizing Enterocolitis (NEC): Meta-analyses, including a systematic review by the ESPGHAN Working Group for Probiotics, Prebiotics & Committee on Nutrition in 2020, have highlighted the effectiveness of LGG in preventing NEC in preterm infants [6].

• Respiratory Tract Infections (RTI): Many studies and meta-analyses have shown LGG's role in reducing the incidence, duration, and severity of ARTI episodes. A meta-analysis evaluating 12 RCTs in daycare settings indicated that LGG significantly reduced the duration of RTIs [7].

• Pediatric IBS: Several RCTs support the clinical efficacy of LGG in pediatric IBS, with studies showing reduction in pain severity and frequency, and improvement in treatment success and abdominal pain symptoms [8].

• Infant Colic: Studies demonstrate the efficacy of LGG in reducing crying and irritability in infant colic, and its positive impact on gut microbiota [9].

• Cow’s Milk Protein Allergy (CMPA): Various studies on LGG in pediatric food allergies have shown improvements in digestive symptoms associated with CMPA, reduction in TNF-α levels, and improvement in oral tolerance and allergic manifestations [10].

LGG's extensive research and diverse applications make it a cornerstone in the field of probiotics, particularly in pediatric health.